Company profile
Bio-Path Holdings, Inc.
OTC: BPTH · Healthcare · Biotechnology
#1163 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 34GM —SS 27
v0.1 · 25/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ workforce scale, revenue growth (YoY)
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$9.9M
Employees
1
as of 2026-09-26
Market cap
$4.7k
as of 2026-09-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02018
Net income-$9.9M-$9.9M2024
Operating income-$12.0M-$12.0M2024
Total assets$3.9M$3.9M2024
Liabilities$3.7M$3.7M2024
Equity$154.0k$154.0k2024
Revenue trend
FY2015 – FY2018 · USD
FY15
FY15
FY16
FY16
FY16
FY16
FY17
FY18
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Bio-Path Holdings, Inc.’s revenue?
Bio-Path Holdings, Inc. booked $0 in FY2018 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Safeplus International Holdings Limited——PAO Group, Inc.——Arno Therapeutics, Inc.——Life Stem Genetics Inc.——Innovation1 Biotech Inc.——ForU Holdings, Inc.——Neighbors
Harris →Key facts
CEOVikram Paul Grover
SectorHealthcare
IndustryBiotechnology
HeadquartersBellaire, TX
ExchangeOTC: BPTH
Employees1
IPO date2008-03-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.